PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
289 / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-41.24%
Negative revenue growth while ECL.AX stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-44.89%
Negative gross profit growth while ECL.AX is at 0.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
-73.94%
Negative EBIT growth while ECL.AX is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-86.49%
Negative operating income growth while ECL.AX is at 0.00%. Joel Greenblatt would press for urgent turnaround measures.
-69.08%
Negative net income growth while ECL.AX stands at 0.00%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-70.00%
Negative EPS growth while ECL.AX is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-70.00%
Negative diluted EPS growth while ECL.AX is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.93%
Share change of 0.93% while ECL.AX is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
-2.64%
Reduced diluted shares while ECL.AX is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-185.61%
Negative OCF growth while ECL.AX is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-187.98%
Negative FCF growth while ECL.AX is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
170.06%
Positive 10Y revenue/share CAGR while ECL.AX is negative. John Neff might see a distinct advantage in product or market expansion over the competitor.
-15.95%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
39.74%
Positive 3Y CAGR while ECL.AX is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
-428.17%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-180.20%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-72.79%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
498.00%
Net income/share CAGR above 1.5x ECL.AX's 12.77% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
-40.20%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
99.33%
Positive short-term CAGR while ECL.AX is negative. John Neff would see a clear advantage in near-term profit trajectory.
935.04%
10Y equity/share CAGR above 1.5x ECL.AX's 139.38%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
82.81%
5Y equity/share CAGR at 50-75% of ECL.AX's 136.81%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
85.42%
3Y equity/share CAGR at 75-90% of ECL.AX's 106.52%. Bill Ackman pushes for margin or operational changes to match the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
11.07%
AR growth of 11.07% while ECL.AX is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
0.58%
Inventory growth of 0.58% while ECL.AX is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
-2.85%
Negative asset growth while ECL.AX invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
8.13%
BV/share growth of 8.13% while ECL.AX is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
14.17%
Debt growth of 14.17% while ECL.AX is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
-100.00%
Our R&D shrinks while ECL.AX invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-12.77%
We cut SG&A while ECL.AX invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.